271 related articles for article (PubMed ID: 18459517)
1. Evaluation of injectable CaHA for the treatment of mid-face volume loss.
Beer K; Yohn M; Cohen JL
J Drugs Dermatol; 2008 Apr; 7(4):359-66. PubMed ID: 18459517
[TBL] [Abstract][Full Text] [Related]
2. A multicenter, randomized trial comparing calcium hydroxylapatite to two hyaluronic acids for treatment of nasolabial folds.
Moers-Carpi M; Vogt S; Santos BM; Planas J; Vallve SR; Howell DJ
Dermatol Surg; 2007 Dec; 33 Suppl 2():S144-51. PubMed ID: 18086052
[TBL] [Abstract][Full Text] [Related]
3. A multicenter, 47-month study of safety and efficacy of calcium hydroxylapatite for soft tissue augmentation of nasolabial folds and other areas of the face.
Sadick NS; Katz BE; Roy D
Dermatol Surg; 2007 Dec; 33 Suppl 2():S122-6; discussion S126-7. PubMed ID: 18086049
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of injectable calcium hydroxylapatite for the treatment of facial lipoatrophy associated with human immunodeficiency virus.
Carruthers A; Carruthers J
Dermatol Surg; 2008 Nov; 34(11):1486-99. PubMed ID: 18811715
[TBL] [Abstract][Full Text] [Related]
5. Calcium hydroxylapatite versus nonanimal stabilized hyaluronic acid for the correction of nasolabial folds: a 12-month, multicenter, prospective, randomized, controlled, split-face trial.
Moers-Carpi MM; Tufet JO
Dermatol Surg; 2008 Feb; 34(2):210-5. PubMed ID: 18093199
[TBL] [Abstract][Full Text] [Related]
6. Physician and patient satisfaction after use of calcium hydroxylapatite for cheek augmentation.
Moers-Carpi M; Storck R; Howell DJ; Ogilvie P; Ogilvie A
Dermatol Surg; 2012 Jul; 38(7 Pt 2):1217-22. PubMed ID: 22759259
[TBL] [Abstract][Full Text] [Related]
7. A 52-month summary of results using calcium hydroxylapatite for facial soft tissue augmentation.
Tzikas TL
Dermatol Surg; 2008 Jun; 34 Suppl 1():S9-15. PubMed ID: 18547188
[TBL] [Abstract][Full Text] [Related]
8. [Polylactic acid injections: usefullness for the treatment of facial lipoatrophy in HIV+ patients under tritherapy].
Piquet M; Brignol L; Chatelain B; Rey D; Ricbourg B; Meyer C
Rev Stomatol Chir Maxillofac; 2007 Dec; 108(6):496-504. PubMed ID: 17675198
[TBL] [Abstract][Full Text] [Related]
9. Prospective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: one-year durability.
Silvers SL; Eviatar JA; Echavez MI; Pappas AL
Plast Reconstr Surg; 2006 Sep; 118(3 Suppl):34S-45S. PubMed ID: 16936543
[TBL] [Abstract][Full Text] [Related]
10. Six-month safety results of calcium hydroxylapatite for treatment of nasolabial folds in Fitzpatrick skin types IV to VI.
Marmur ES; Taylor SC; Grimes PE; Boyd CM; Porter JP; Yoo JY
Dermatol Surg; 2009 Oct; 35 Suppl 2():1641-5. PubMed ID: 19708876
[TBL] [Abstract][Full Text] [Related]
11. A randomized, bilateral, prospective comparison of calcium hydroxylapatite microspheres versus human-based collagen for the correction of nasolabial folds.
Smith S; Busso M; McClaren M; Bass LS
Dermatol Surg; 2007 Dec; 33 Suppl 2():S112-21; discussion S121. PubMed ID: 18086048
[TBL] [Abstract][Full Text] [Related]
12. The role of calcium hydroxylapatite (Radiesse) in nonsurgical aesthetic rejuvenation.
Lizzul PF; Narurkar VA
J Drugs Dermatol; 2010 May; 9(5):446-50. PubMed ID: 20480786
[TBL] [Abstract][Full Text] [Related]
13. A retrospective review of calcium hydroxylapatite for correction of volume loss in the infraorbital region.
Hevia O
Dermatol Surg; 2009 Oct; 35(10):1487-94. PubMed ID: 19614938
[TBL] [Abstract][Full Text] [Related]
14. Hyaluronic acid new formulation: experience in HIV-associated facial lipoatrophy.
Bechara FG; Gambichler T; Brockmeyer NH; Sand M; Altmeyer P; Hoffmann K
Dermatology; 2008; 217(3):244-9. PubMed ID: 18663308
[TBL] [Abstract][Full Text] [Related]
15. Open-Label, Post-Marketing Study to Evaluate the Performance and Safety of Calcium Hydroxylapatite With Integral Lidocaine to Correct Facial Volume Loss.
Muti GF
J Drugs Dermatol; 2019 Jan; 18(1):86-91. PubMed ID: 30681803
[TBL] [Abstract][Full Text] [Related]
16. Sustained efficacy and high patient satisfaction after cheek enhancement with a new hyaluronic acid dermal filler.
Kestemont P; Cartier H; Trevidic P; Rzany B; Sattler G; Kerrouche N; Dhuin JC
J Drugs Dermatol; 2012 Jan; 11(1 Suppl):s9-16. PubMed ID: 22497039
[TBL] [Abstract][Full Text] [Related]
17. Radiographic and computed tomographic studies of calcium hydroxylapatite for treatment of HIV-associated facial lipoatrophy and correction of nasolabial folds.
Carruthers A; Liebeskind M; Carruthers J; Forster BB
Dermatol Surg; 2008 Jun; 34 Suppl 1():S78-84. PubMed ID: 18547186
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a calcium hydroxylapatite-based implant (Radiesse) for facial soft-tissue augmentation.
Jansen DA; Graivier MH
Plast Reconstr Surg; 2006 Sep; 118(3 Suppl):22S-30S, discussion 31S-33S. PubMed ID: 16936541
[TBL] [Abstract][Full Text] [Related]
19. Clinical, histologic and electron microscopic findings after injection of a calcium hydroxylapatite filler.
Marmur ES; Phelps R; Goldberg DJ
J Cosmet Laser Ther; 2004 Dec; 6(4):223-6. PubMed ID: 16020207
[TBL] [Abstract][Full Text] [Related]
20. Hyperdiluted Calcium Hydroxylapatite 1: 2 for Mid and Lower Facial Skin Rejuvenation: Efficacy and Safety.
Rovatti PP; Pellacani G; Guida S
Dermatol Surg; 2020 Dec; 46(12):e112-e117. PubMed ID: 32205749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
